Finance

Lists
Q3 2026 earnings • in 2 days
See details
ABSI:NASDAQ
Absci Corp
$10.80
+6.19%
(+0.63) 1D
$10.80
0.00% (0.00)
After hours
Closed: Nov 9, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ABSI...
Open
$10.10
High
$11.22
Low
$9.92
Mkt. cap
1.85B
Avg. vol.
4.06M
Volume
3.76M
52-wk high
$12.54
52-wk low
$2.24
EPS
-$0.80
Beta
2.22
Shares outstanding
171.61M
No. of employees
140
Open
$10.10
High
$11.22
Low
$9.92
Mkt. cap
1.85B
Avg. vol.
4.06M
Volume
3.76M
52-wk high
$12.54
52-wk low
$2.24
EPS
-$0.80
Beta
2.22
Shares outstanding
171.61M
No. of employees
140
News stories
From web sources and news partners
About Absci Corp
CEO-
Employees140
Founded2011
HeadquartersVancouver, Washington, United States
SectorHealth Care
IndustryBiotechnology
Websiteabsci.com
Analyst ratings
Based on 10 analysts giving stock ratings to ABSI in the past 3 months
Strong buy
Buy
9
Hold
1
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for ABSI in the last 3 months.
Highest
Current $10.80
$20.00 (+85.19%)
Average
$14.56 (+34.81%)
Lowest
$10.00 (-7.41%)
Analyst
Recommendation
Action
Price target
Projected
Date
Andrew Tsai
Jefferies
Buy
Initiated
$14.00
+29.6%
10/29/2026
Swayampakula Ramakanth
H.C. Wainwright
Buy
Maintained
$16.00
+48.1%
10/20/2026
Scott Schoenhaus
KeyBanc
Buy
Maintained
$20.00
+85.2%
10/16/2026
Unknown Analyst
KeyBanc
Buy
Maintained
$20.00
+85.2%
10/16/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
$15.00
+38.9%
10/12/2026
Kambiz Yazdi
BTIG
Buy
Reiterated
$16.00
+48.1%
10/06/2026
Brendan Smith
TD Cowen
Buy
Maintained
-
-
09/30/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
$16.00
+48.1%
09/24/2026
Gil Blum
Needham
Buy
Maintained
$11.00
+1.9%
09/23/2026
Sean Laaman
Morgan Stanley
Hold
Reiterated
$10.00
-7.4%
08/17/2026
Debanjana Chatterjee
JonesTrading
Buy
Maintained
$13.00
+20.4%
08/12/2026
Srikripa Devarakonda
Truist Financial
Buy
Reiterated
$17.00
+57.4%
07/02/2026
Vamil Divan
Guggenheim
Buy
Reiterated
$15.00
+38.9%
06/25/2026
Mani Foroohar
Leerink Partners
Buy
Initiated
$12.00
+11.1%
06/04/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$10.00
-7.4%
05/10/2026
Next call in 2 days
Thu, Nov 12, 8:00 AM
Fiscal period
Q3 2026
- / -$0.20
Revenue / Est. (USD)
- / 581.70K
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
378.00K
650.00K
215.00K
318.00K
Cost of goods sold
19.25M
24.65M
19.28M
22.62M
Cost of revenue
19.25M
24.65M
19.28M
22.62M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.44M
8.62M
9.06M
9.16M
Operating expense
11.28M
11.44M
11.79M
11.86M
Total operating expenses
30.53M
36.09M
31.06M
34.48M
Operating income
-30.15M
-35.44M
-30.85M
-34.16M
Other non operating income
1.60M
1.35M
1.28M
990.00K
EBT including unusual items
-28.60M
-29.72M
-29.58M
-33.17M
EBT excluding unusual items
-28.60M
-34.12M
-29.58M
-33.17M
Income tax expense
104.00K
-162.00K
18.00K
40.00K
Effective tax rate
-0.36%
0.55%
-0.06%
-0.12%
Other operating expenses
-
-
-
-
Net income
-28.71M
-29.56M
-29.60M
-33.21M
Net profit margin
-7,594.18%
-4,548.00%
-13,766.98%
-10,443.40%
Earnings per share
-0.20
-0.23
-0.19
-0.21
Interest and investment income
-
-
-
-
Interest expense
-45.00K
-29.00K
-18.00K
-2.00K
Net interest expenses
-45.00K
-29.00K
-18.00K
-2.00K
Depreciation and amortization charges
2.84M
2.83M
2.73M
2.70M
EBITDA
-27.31M
-32.61M
-28.12M
-31.46M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps